COMPANY PROFILE

Lemonex

Explore full profile

Innovative drug delivery and screening technologies for gene therapy, cancer immunotherapy, and antiviral drugs

Seoul, South KoreaFounded 2013Biotech & Life Sciences

Valuation $50–100M Last recorded · 2021

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Lemonex

Lemonex is a global biotherapeutics biotechnology company specializing in next-generation drug delivery and biosensor technologies. The company's core product, DegradaBALL, enables precise control over drug size, concentration, and stability, making it highly effective for gene therapy, cancer immunotherapy, antibody therapy, and synthetic drugs. Lemonex also offers PANGO technology, a cutting-edge drug screening platform optimized for rapid identification of antiviral drugs from extensive drug candidate libraries.

Lemonex serves pharmaceutical companies and research institutions focused on developing advanced therapeutic agents. Operating in the biotherapeutics market, the company generates revenue through the commercialization of its proprietary technologies and collaborative partnerships.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2013
Headquarters: Seoul, South Korea
Employees: 6
Open positions: None listed
Dealroom signal: 72.7/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biomaterials, Spinout, Nanomaterials, Coating Technology, Advanced Materials
Technology: Hardware, Deep Tech, Nanotech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES C✓Equity / VC	Apr 2021	$13M	$52M	SmileGate Investment · Metaine Best · Division Investment	↗
SERIES B✓Equity / VC	Dec 2018	$9.6M	$39M	Daesung Private Equity Group · Shinhan Capital · IBK Capital · Union Investment Partners	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Lemonex website traffic

Latest recorded traffic for Lemonex is 2.8K monthly website visits, up 55.6% over the last three months. Lemonex's team declined 14.3% over the past year.

Latest monthly visits2.8K 3-month web change+55.6% 1-year team growth-14.3%

Monthly website visitsOct 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CBConstructive BioRealising the potential of genome rewriting to drive the next generation of bioprocesses and biopharmaceuticals	Cambridge, United Kingdom	Operational	71	$115M	$285M
GBGreen Elephant BiotechSustainable expansion solutions for adherent cell culture	Gießen, Germany	Operational
EBEV BiotechMicrobial cell factory (MCF) strain development company	Groningen, Netherlands	Operational
JBJiangsu Shenji BiotechnologyA developer of POCT diagnostic products and tumor molecular diagnostic products	Nanjing City, China	Operational
INIntellegensHelping clients accelerate innovation by using our unique deep learning solutions to extract valuable information from existing processes and data	Cambridge, United Kingdom	Operational
AHAuxilium HealthBiomaterial platform for proactive wound infection care	Akron, United States	Operational
BIBioOraCell therapy for every patient in need	Wellington, New Zealand	Operational
NHNano HybridsDeveloping hybrid core-shell nanoparticles to address challenges of high-impact technological fields	Amsterdam, Netherlands	Operational